CVS Health Co. (NYSE:CVS) Stock Position Trimmed by Tidal Investments LLC

Tidal Investments LLC decreased its position in CVS Health Co. (NYSE:CVS) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 104,037 shares of the pharmacy operator’s stock after selling 7,973 shares during the period. Tidal Investments LLC’s holdings in CVS Health were worth $4,670,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Coppell Advisory Solutions LLC grew its holdings in CVS Health by 17.3% in the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator’s stock worth $56,000 after buying an additional 189 shares in the last quarter. EagleClaw Capital Managment LLC grew its stake in shares of CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock worth $275,000 after purchasing an additional 200 shares in the last quarter. Manchester Capital Management LLC grew its stake in shares of CVS Health by 4.8% in the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock worth $200,000 after purchasing an additional 204 shares in the last quarter. Angeles Investment Advisors LLC raised its stake in shares of CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 204 shares in the last quarter. Finally, Rogco LP lifted its holdings in CVS Health by 3.2% in the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock worth $303,000 after purchasing an additional 210 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 1.5%

CVS stock opened at $63.73 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The firm has a market capitalization of $80.62 billion, a P/E ratio of 17.41, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $72.51. The company’s 50 day simple moving average is $66.48 and its 200-day simple moving average is $59.32.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.31 EPS. As a group, equities research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were issued a $0.665 dividend. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.17%. CVS Health’s dividend payout ratio is 63.48%.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This represents a 47.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.22% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have commented on CVS. Leerink Partnrs raised shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Monday, May 5th. Royal Bank of Canada upped their target price on CVS Health from $74.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 5th. Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. boosted their price objective on CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 18th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $74.94.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.